Revlimid — CareFirst (Caremark)
Histiocytic Neoplasms (Langerhans cell histiocytosis, Rosai-Dorfman disease)
Initial criteria
- Treatment as a single agent.
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen.
Approval duration
12 months